C5a Receptor
Showing the single result
-
CELT-058 C5a receptor fluorescent antagonist (646/662)
For research use only10 µg vial can be used to prepare 87.32 µL of a 100 µM stock solution, providing enough volume for 8 assays at a working concentration of 100 nM.
Please note that the required concentration may vary depending on the specific assay design.
476,00€View moreProduct on backorder. Contact us at info@celtarys.com for an estimated delivery date.
PERTE SALUD Proyecto Nº: IDI-2025-0751
Título: TERAPIAS AVANZADAS EN INMUNOONCOLOGÍA: UNA ESTRATEGIA INNOVADORA
BASADA EN LA DEGRADACIÓN DIRIGIDA DE GPCR EN EL EJE ADENOSINÉRGICOS
EIC Pathfinder; Project name: Unisens; Universal GPCR Activity Sensor for Next Generation Drug Discovery
Esta entidad fue beneficiaria de las ayudas para la ejecución de acciones de promoción exterior de las empresas gallegas. El objetivo principal de estas ayudas es incentivar la realización de acciones de promoción exterior generadoras de ventajas competitivas. El resultado que se pretende conseguir es el impulso de las pymes y sus productos y servicios, aumentando el número de empresas de base exportadora.
Celtarys Research is beneficiary of a WomenTechEU grant supporting deep-tech start-ups led by women
Principia 2021 Program
Celtarys staff has been funded by the Xunta de Galicia within the framework of the PRINCIPIA 2021 Program of the Galician Innovation Agency (GAIN)
InnovaPEME Program
Celtarys Innovation Plan has been funded by the InnovaPEME 2022 program of the Galician Innovation Agency (GAIN)
Bonos de Innovación de Celtarys Research (026)
Para promover o desenvolvemento tecnolóxico, a innovación e unha investigación de calidade. Esta operación está financiada pola Xunta de Galicia, a través de axudas concedidas pola Axencia Galega de Innovación, dentro do programa de axudas a empresa Bonos de innovación 2022.
Celtarys Research is part of the public-private consortium developing the project PREDICTEAM
New prognostic quantitative biomarker assays for predicting patient response to immune checkpoint inhibitor (ICI) treatment
NEOTEC · CDTI — Ministerio de Ciencia e Innovación
The Project ‘New chemical conjugation technology for therapeutic targets’ has been founded by CDTI under its program NEOTEC. The NEOTEC program objective is supporting the establishment and consolidation of technology-based enterprises. A technology-based company (EBT) is a company whose activity focuses on the exploitation of products or services that require the use of technologies and knowledge developed since the research activity. The EBT base their business strategy or activity in the intensive domain of scientific and technical knowledge. Budget awarded: 416.177€ | Execution dates: 1/1/2023 – 31/03/2024